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The CYFIP1/SRA1 gene is located in a chromosomal
region linked to various neurological disorders,
including intellectual disability, autism, and schizo-
phrenia. CYFIP1 plays a dual role in two apparently
unrelated processes, inhibiting local protein synthe-
sis and favoring actin remodeling. Here, we show
that brain-derived neurotrophic factor (BDNF)-driven
synaptic signaling releases CYFIP1 from the transla-
tional inhibitory complex, triggering translation of
target mRNAs and shifting CYFIP1 into the WAVE
regulatory complex. Active Rac1 alters the CYFIP1
conformation, as demonstrated by intramolecular
FRET, and is key in changing the equilibrium of the
two complexes. CYFIP1 thus orchestrates the two
molecular cascades, protein translation and actin
polymerization, each of which is necessary for cor-
rect spine morphology in neurons. The CYFIP1 inter-
actome reveals many interactors associated with
brain disorders, opening new perspectives to defineNeuregulatory pathways shared by neurological disabil-
ities characterized by spine dysmorphogenesis.
INTRODUCTION
Genetic alterations of the pathways controlling local protein syn-
thesis in neurons contribute to diverse intellectual disabilities (ID)
and autism spectrum disorders (ASDs) (Ehninger and Silva,
2009). These disorders are synaptopathies (Ehninger and Silva,
2009) in which dysgenesis of dendritic spines is a recurrent
anatomical feature (Penzes et al., 2011). Fragile X syndrome
(FXS) is the most common form of inherited ID and a frequent
monogenic cause of ASD (Belmonte and Bourgeron, 2006;
Hatton et al., 2006; Jacquemont et al., 2007; Turk, 2011).
Patients with FXS display dendritic spine defects (Irwin et al.,
2001), neurodevelopmental delay, and autistic-like phenotype
(Jacquemont et al., 2007). FXS is due to loss of function of the
RNA-binding protein FMRP (Bagni et al., 2012; Bassell and War-
ren, 2008), which regulates dendritic targeting of mRNAs (Dic-
tenberg et al., 2008) and controls protein synthesis and mRNA
decay in neuronal soma and at synapses (Bassell and Warren,
2008). High-throughput screenings (Brown et al., 2001; Darnellron 79, 1169–1182, September 18, 2013 ª2013 Elsevier Inc. 1169
Figure 1. CYFIP1 Participates in Two Distinct Complexes
(A) Analysis of the crystal structure of theWRC.Upper panel: the eIF4E-binding site (light red, aa 733–751 of the humanprotein) of CYFIP1 (red) is partially occluded
by NCKAP1 (green). Lower panels: left, a detail showing the interaction between CYFIP1 (red) and eIF4E (yellow); right, a detail showing that Lys743 is covered by
NCKAP1 (green) when CYFIP1 (red) is within the WRC. Lys743 that is crucial for the interaction with eIF4E is highlighted with an arrowhead in both panels.
(B) CYFIP1 IP from synaptoneurosomes. Lane 1, input (1/100); lane 2, CYFIP1 IP; lane 3, control IP (rabbit IgGs). Lanes shown belong to the same blot, n = 6.
(C) NCKAP1 and eIF4E IPs from synaptoneurosomes. Lane 1, input (1/100); lane 2, NCKAP1 IP; lane 3, control (rIgGs) IP; lane 4, eIF4E IP; lane 5, control (mIgGs)
IP. Lanes shown belong to the same blot, n = 3.
See also Figure S1 and Table S1.
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et al., 2003) have revealed that a wide array of neuronal mRNAs
is targeted by FMRP, suggesting that simultaneous dysregula-
tion of many proteins contributes to FXS.
A key functional partner of FMRP is the cytoplasmic FMRP-
interacting protein 1, CYFIP1 (Napoli et al., 2008; Schenck
et al., 2003; Schenck et al., 2001) also known as ‘‘specific
Rac1-activated’’ (SRA1) protein (Kobayashi et al., 1998).CYFIP1
is located within a hot spot for ASD (chr15q11.2), close to a re-
gion critical for two ASD-related syndromes: the Angelman and
Prader-Willi syndromes. Microdeletions or microduplications of
the region, includingCYFIP1 and three other genes, cosegregate
with cognitive disabilities and ASD (Cooper et al., 2011; Door-
nbos et al., 2009; Leblond et al., 2012; Nishimura et al., 2007;
van der Zwaag et al., 2010; von der Lippe et al., 2010). CYFIP1
messenger RNA (mRNA) is downregulated in a subgroup of
FXS patients who have the Prader-Willi phenotype and show
severe ASD and obsessive-compulsive behavior (Nowicki
et al., 2007). In addition, CYFIP1 has recently been linked to
schizophrenia (SCZ) (Tam et al., 2010; Zhao et al., 2012).
Together with FMRP, CYFIP1 represses neuronal protein syn-
thesis: FMRP tethers specific mRNAs to CYFIP1, which in turn
sequesters the cap-binding protein eIF4E, thereby preventing
initiation of translation (Napoli et al., 2008). Upon activation of
the brain-derived neurotrophic factor (BDNF)/NT-3 growth factor
receptor (TrkB) or group I metabotropic glutamate receptors
(mGluRs), CYFIP1 is released from eIF4E and translation ensues
(Napoli et al., 2008). Furthermore, CYFIP1 is part of the Wave
Regulatory Complex (WRC), a heteropentamer containing also
WAVE1/2/3, ABI1/2, NCKAP1 and HPSC300 (Takenawa and
Suetsugu, 2007). The WRC regulates the actin-nucleating activ-
ity of the Arp2/3 complex and it can be activated through the
small GTPase Rac1, kinases, and phospholipids (Chen et al.,
2010; Eden et al., 2002; Lebensohn and Kirschner, 2009). In1170 Neuron 79, 1169–1182, September 18, 2013 ª2013 Elsevier Incparticular, the Rac1 signaling can activate the WRC through
CYFIP1 (Chen et al., 2010; Eden et al., 2002; Kobayashi et al.,
1998; Schenck et al., 2003; Steffen et al., 2004). Rearrangements
of the actin cytoskeleton strongly influence the formation, retrac-
tion, motility, stability, and shape of the dendritic spines (Tada
and Sheng, 2006), and genetic ablation of WRC components
affects spine morphology and excitability (Grove et al., 2004;
Kim et al., 2006; Soderling et al., 2007; Wiens et al., 2005). How-
ever, the interplay of this process with other events regulating
spine function, such as local translation, is still unknown.
Here, wedemonstrate that active Rac1 changes the equilibrium
between twodistinctCYFIP1complexes,activating the translation
of mRNAs important for synaptic structure and function, such as
Arc/Arg3.1 mRNA. This switch occurs through a conformational
change in CYFIP1, detectable by Fo¨rster resonance energy
transfer (FRET). Knockdown of Cyfip1 or mutations in the regions
interacting with eIF4E or WRC produce dendritic spine defects
resembling those found in FXS and other synaptopathies. These
findings shed light on the molecular mechanisms that tune the
balance between translational control and actin remodeling at
synapses. The identification of interaction partners of CYFIP1
suggests that neurological disorders characterized by spine
dysmorphogenesis might be due to perturbations in the balance
between these two CYFIP1 interconnected pathways.
RESULTS
CYFIP1 Is Part of Two Complexes
To dissect the CYFIP1 function and its possible crosstalk with
the FMRP-eIF4E translational complex and the actin-regulatory
complex WRC, we investigated the structural organization of
the two CYFIP1 complexes. According to the crystal structure
of the WRC that includes CYFIP1 (Chen et al., 2010), NCKAP1
interacts with CYFIP1 over a large surface (Figure 1A, upper.
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et al., 2008) is covered by NCKAP1 and therefore is not acces-
sible to solvent when CYFIP1 is in the WRC (Figure 1A, bottom
panels, Table S1). These structural data indicate that the same
CYFIP1 molecule cannot simultaneously interact with the WRC
and eIF4E.
Synapses are severely affected in FXS and other neurological
disorders (Fiala et al., 2002; Penzes et al., 2011; Valnegri et al.,
2012). Electron microscopy (EM) and biochemical studies
revealed that CYFIP1, at synapses, is enriched in postsynaptic
compartments (FigureS1available online). Inmousecortical syn-
aptoneurosomes, CYFIP1 coimmunoprecipitates with FMRP,
eIF4E, NCKAP1, andWAVE1 (Figure 1B). Furthermore, immuno-
precipitation of NCKAP1 revealed the presence of CYFIP1 but
not eIF4E, whereas immunoprecipitation of the eIF4E complex
detected CYFIP1 but not NCKAP1 (Figure 1C). We conclude
that CYFIP1 engages in two distinct complexes.
Synaptic Stimulation Changes CYFIP1 Distribution
between the Two Molecular Complexes
Synaptic activity leads to an increase of protein synthesis as
well as actin remodeling (Bramham, 2008). Given the presence
of CYFIP1 in the FMRP-eIF4E translational complex and the
actin-regulatory complex WRC, we investigated whether its dis-
tribution over these two complexes might change after synaptic
stimulation. Therefore, we stimulated cortical neurons with
BDNF at 15 days in vitro (DIV) (Figure S2A), a stage when
FMRP, CYFIP1, and eIF4E are highly expressed and neurons
are mature (Figure S2A). We stimulated neurons with BDNF,
which induces translation (Aakalu et al., 2001; Schratt et al.,
2004; Takei et al., 2004) and actin remodeling (Bramham,
2008), and followed the subsequent changes in the colocaliza-
tion of CYFIP1 with eIF4E or NCKAP1. Stimulation by BDNF
significantly reduced the degree of CYFIP1-eIF4E colocaliza-
tion, and concomitantly increased the number of CYFIP1-
NCKAP1 puncta, suggesting that CYFIP1 distribution changes
between these complexes upon TrkB receptor activation (Fig-
ures 2A and S2B). The magnitude of these changes is similar
to those observed with manipulations that alter interactions of
eIF4E with canonical eIF4E-BPs (Costa-Mattioli et al., 2009;
Richter and Klann, 2009; Sonenberg and Hinnebusch, 2009).
These changes were observed 15 min after BDNF stimulation
(Figure S2C). Only a very small proportion of CYFIP1 remained
not engaged within these two complexes (15% according to
the colocalization data). Consistently, blue native PAGE (BN-
PAGE) revealed that the majority, if not all, of CYFIP1 is part
of high molecular weight complexes (Figure S2D). Based on
these data, we infer that a ‘‘free’’ CYFIP1 pool is minor.
We then aimed at identifying the factors regulating this equi-
librium. A candidate is Rac1, because in its active form (GTP-
Rac1), it interacts with CYFIP1 (Kobayashi et al., 1998) and
favors WRC activation (Chen et al., 2010; Eden et al., 2002;
Schenck et al., 2003; Steffen et al., 2004). To test this hypothesis,
we used NSC23766, a specific inhibitor of Rac1 activation (Gao
et al., 2004) (Figure S2E). Addition of NSC23766 before BDNF
stimulation prevented the redistribution of CYFIP1 (Figure 2A),
indicating that active Rac1 is needed for the effect of BDNF on
the CYFIP1 complexes. To further monitor the dynamics ofNeuCYFIP1 redistribution, we quantified the changes in fluores-
cence of EYFP-CYFIP1, Cerulean-NCKAP1, and eIF4E-mCherry
in spines of BDNF-stimulated primary neurons over time (Fig-
ure S3). We observed that the ratio of Cerulean-NCKAP1 over
EYFP-CYFIP1 steadily increases, indicating a build-up of WRC
(Figure S3C).
CYFIP1 redistribution between eIF4E- and NCKAP1-contain-
ing complexes was further corroborated by biochemical evi-
dence in isolated synaptoneurosomes: BDNF stimulation
increased the amount of CYFIP1 coprecipitating with NCKAP1,
and conversely reduced its binding to eIF4E; the Rac1 inhibitor
was able to prevent the CYFIP1 redistribution (Figure 2B).
To investigate whether active Rac1 directly changes the ability
of CYFIP1 to bind eIF4E, we used GTP-Rac1 as exogenous
competitor in m7GTP chromatography on cortical lysates.
Indeed, increasing concentrations of GTP-Rac1 reduced the
degree of binding of CYFIP1 to eIF4E, whereas inactive Rac1
(GDP-Rac1) had no effect (Figure 2C). The association of FMRP
to eIF4E was also reduced, whereas no changes were observed
for eIF4G.NCKAP1did not copurify at allwith eIF4E, showing that
the assay specifically allowed isolation of eIF4E-associated com-
plexes. These data indicate that exogenous active Rac1 partially
dissolves a preassembled CYFIP1-eIF4E complex. To address
whether Rac1 also drives the distribution of CYFIP1 over the
two complexes in other physiological and cellular contexts, we
monitored the CYFIP1-eIF4E complex upon serum restoration
in serum-deprived HEK293T cells (Figure S4A). In agreement
with our findings in brain, CYFIP1 and FMRP were rapidly
released from eIF4E upon addition of serum, and then slowly
reassociated (Figure S4B), whereas Rac1 inhibitor abolished
the release of the translational inhibitory complex (Figure S4C).
Finally, we investigated how active Rac1 changes the binding
affinity of CYFIP1 for eIF4E and thereby favors the association of
CYFIP1 with the WRC. A possibility is that CYFIP1 exists in two
different conformations, and that GTP-Rac1 triggers a transition
between the two. The crystal structure of the WRC showed
that CYFIP1 has a planar conformation (Chen et al., 2010). We
extracted CYFIP1 from the WRC and let it evolve in a molecular
dynamics simulation for 135 ns. We obtained a CYFIP1 molecule
with a predicted more ‘‘globular’’ conformation and a reduced
distance between the N and C termini (7 nm instead of
12.8 nmmeasured for CYFIP1 in the WRC crystal structure) (Fig-
ure 2D). The consequence of this conformational change is that
the domain carrying the eIF4E-binding site moves toward the
outside (Figure 2D), allowing Lys743 to interact with Glu132 of
eIF4E (Figure 1A) (Napoli et al., 2008). To validate the predicted
second CYFIP1 conformation, we applied intramolecular FRET
on HEK293T cells transfected with a CYFIP1 harboring mCherry
and EGFP at its N and C termini (mCherry-CYFIP1-EGFP) (Fig-
ure 2E). The presence of two fluorescent tags did not inhibit
the interaction of CYFIP1 with eIF4E and NCKAP1 (Figure 2E).
FRET was revealed by measuring the donor’s fluorescence life-
time (for details, see legend to Figure S4D). Only the globular
conformation might result in FRET, due to a distance between
the termini of 7 nm, whereas the separation of 12.8 nm in
the planar conformation would not allow substantial Fo¨rster-
type resonance (R0 = 5 nm) (Albertazzi et al., 2009).
mCherry-CYFIP1-EGFP exhibited significant FRET, indicatingron 79, 1169–1182, September 18, 2013 ª2013 Elsevier Inc. 1171
Figure 2. Upon BDNF Treatment CYFIP1 Shifts between eIF4E and WRC through a Conformational Change Induced by Active Rac1
(A) BDNF changes CYFIP1-eIF4E and CYFIP1-NCKAP1 colocalization in a Rac1-dependent manner. Left: representative dendrites costained for CYFIP1-eIF4E
(yellow, upper row) and CYFIP1-NCKAP1 (cyan, lower row; scale bar represents 5 mm). See Figure S2B for single staining (green, CYFIP1; red, eIF4E; blue,
NCKAP1). Neurons treated with vehicle or BDNF (100 ng/ml for 30min) with/without NSC23766 (200 mM for 10min pretreatment) are shown. Right: percentage of
(legend continued on next page)
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are within range for a Fo¨rster-type interaction. Inhibition of Rac1
activation by NSC23766 further increased the FRET signal,
which is most likely explained by a higher number of molecules
in the more globular conformation, the conformation that allows
CYFIP1 to bind eIF4E. Importantly, these data were confirmed
and further extended in primary cortical neurons (Figure 2F). To
promote the engagement of mCherry-CYFIP1-EGFP in the
translation inhibitory complexes, we treated primary neurons
with the panTrk inhibitor k252a (Petroulakis and Wang, 2002).
As expected, such treatment decreased ARC synthesis and
eIF4E phosphorylation (Gingras et al., 1999) (Figure S4E). Under
these conditions, a significant FRET was detected in neurons
transfected with mCherry-CYFIP1-EGFP. This shows that also
in neurons a subpopulation of CYFIP1 molecules exists in a
more globular conformation. Treatment with BDNF attenuated
the FRET signal, indicating that a fraction of CYFIP1 molecules
switched to the planar conformation. The Rac1 inhibitor blocked
the effects of BDNF and restored the equilibrium back to the
more globular conformation. These data provide independent
experimental support that the switch of CYFIP1 between the
two complexes might be facilitated by a conformational change
mediated by Rac1.
Rac1 Affects the CYFIP1-FMRP Regulated mRNA
Translation
Our findings indicate that Rac1 influences the switch of CYFIP1
from eIF4E to WRC, which predicts that it should also modulate
the translation of CYFIP1-FMRP target mRNAs. To test this
hypothesis, we examined the synthesis of the well-characterized
FMRP target Arc/Arg3.1 (Napoli et al., 2008; Niere et al., 2012;
Park et al., 2008; Zalfa et al., 2003) in primary cortical neurons
at DIV15. As shown in Figure 3, ARC expression was robustly
induced by BDNF, and this effect was due to protein synthesis,
because it was blocked by concomitant treatment with cyclo-
heximide (inhibitor of protein synthesis; Figure 3A) but not
by actinomycin D (inhibitor of transcription; Figure 3B). ARCoverlap expressed by Mander’s coefficient for CYFIP1-eIF4E (black) and CYFIP1
ANOVA) with Bonferroni post hoc test; **p < 0.01, ***p < 0.001). Arrowheads indic
(B) BDNF changes CYFIP1-eIF4E and CYFIP1-NCKAP1 interactions through Rac
(100 ng/ml for 30min) with/without NSC23766 (200 mM for 10min pretreatment). L
4–6, IPs for vehicle, BDNF and BDNF + NSC23766. Right, histogram represent
relative to untreated, control samples (n = 4, paired Student’s t test, *p < 0.05). B
(C) Active Rac1 reduces the affinity of CYFIP1 for eIF4E. Left panel: m7GTP chrom
GDP-Rac1. Lane 1, input (1/100); lane 2, m7GTP chromatography; lanes 3–5, m7
respectively; lanes 6–8, as lanes 3–5 but with GDP–Rac1. Right panel: associatio
repeated-measures ANOVA, *p < 0.05). Bars represent mean ± SEM.
(D) Molecular dynamics simulation of CYFIP1 predicts an alternative conformation
upon the CYFIP1 structure obtained by clustering the conformations that domi
colored). The N-terminal, central, and C-terminal domains of the simulated struc
principal movements during the conformational change.
(E) mCherry-CYFIP1-EGFP coimmunoprecipitates with NCKAP1 and eIF4E. CY
(1/100); lane 2, transfected cells input (1/100); lane 3, IP from mock transfected
(F) Left: sketch showing how FRET reveals a globular CYFIP1 conformation. Right
treatment. Top to bottom: free EGFP and free mCherry (negative control); tande
treated with the pan-Trk inhibitor k252a (100 nM for 24 hr); mCherry-CYFIP1-EG
Rac1 inhibitor NSC23766 (200 mM for 10min pretreatment) followed by BDNF trea
**p < 0.01, ***p < 0.001. Bars represent mean ± SEM.
See also Figures S2 and S3.
Neusynthesis triggered by BDNF was completely abolished by pre-
treatment with NSC23766 (Figures 3A and 3B). These effects
were not due to interference with TrkB activation or its
signaling cascade, because BDNF-induced TrkB and ERK1/2
phosphorylation was not affected by NSC23766 (Figure S4F),
indicating that Rac1 inhibition does not disrupt primarily TrkB
signaling. When prolonged activation of TrkB was blocked with
Dynasore (a chlatrin-dependent endocytosis inhibitor), ARC
levels were still induced by BDNF.
To finally demonstrate that Rac1 requires CYFIP1 and FMRP
as downstream effectors to regulate ARC synthesis, Cyfip1
knocked-down or Fmr1 knock-out (KO) neurons were stimulated
withBDNFwithorwithoutNSC23766.Cyfip1wasknocked-down
in cortical neurons (DIV9) with lentivirus carrying a ‘‘short hairpin’’
(sh) RNA directed against Cyfip1 or a scrambled shRNA (i.e., an
RNA hairpin with a random sequence). Three independent
shRNAs were tested, and the shRNA with highest efficiency in
knockingdownCyfip1 (shRNA319;FigureS5A)wasused for sub-
sequent experiments. We found that both CYFIP1 and FMRP
affect basal and activity-induced ARC synthesis. When CYFIP1
expression was reduced to 16% (Figure S5A), ARC basal levels
were significantly increased (Figure 3C). Moreover, ARC was
robustly upregulated after BDNF treatment in control, but not in
Cyfip1-silenced neurons; also the Rac1 inhibitor NSC23766 did
not affect ARC levels in CYFIP1-deficient cells (Figure 3C). Simi-
larly, loss of FMRP increased ARC basal expression (Figure 3C).
Furthermore, ARC synthesis triggered by BDNF was much lower
in Fmr1 KO neurons compared with wild-type (WT); inhibition of
Rac1 activation before BDNF stimulation blocked ARC synthesis
in WT as well as the residual synthesis in Fmr1 KO neurons,
whereas no effect was observed in Cyfip1-silenced neurons
(Figure 3C). Fmr1 KO neurons silenced for Cyfip1 phenocopied
CYFIP1-deficient neurons, further confirming that FMRP and
CYFIP1 act in the same pathway (Figure 3C).
Wealso investigatedARC levels inmicewhereCYFIP1 expres-
sion was genetically reduced. Because Cyfip1 KO animals are
embryonic-lethal (our observation and Bozdagi et al., 2012), we-NCKAP1 (white) (three dendrites from at least ten neurons/condition; one-way
ate colocalization puncta. Bars represent mean ± SEM.
1 activation. Left: CYFIP1 IP from synaptoneurosomes stimulated with BDNF
ane 1, inputs (1/100) for vehicle; lane 2, BDNF; lane 3, BDNF +NSC23766; lanes
s CYFIP1-eIF4E (black) and CYFIP1-NCKAP1 (white) coimmunoprecipitation
ars represent mean ± SEM.
atography on cortical extracts after incubation with exogenous GTP-Rac1 or
GTP chromatography in the presence of 0.45, 0.91, or 1.36 mM of GTP-Rac1,
n of CYFIP1 (black) and FMRP (gray) to eIF4E as percentage to vehicle (n = 6;
. Superposition of the CYFIP1 X-ray structure in the WRC (‘‘planar,’’ light gray)
nate the end of the 135-ns molecular dynamics simulation (more ‘‘globular,’’
ture are shown in blue, red, and green, respectively. The arrows indicate the
FIP1 was immunoprecipitated with an anti-GFP antibody. Lane 1, mock input
cells; lane 4, IP from transfected cells.
: in neurons CYFIP1 exists in a globular conformation that changes after BDNF
m mCherry-EGFP (intramolecular FRET); mCherry-CYFIP1-EGFP in neurons
FP after BDNF (100 ng/ml for 30 min) treatment; mCherry-CYFIP1-EGFP after
tment. At least n = 30, one-way ANOVAwith Bonferroni post hoc test, *p < 0.05,
ron 79, 1169–1182, September 18, 2013 ª2013 Elsevier Inc. 1173
Figure 3. Rac1 Regulates CYFIP1 and
FMRP-Dependent mRNA Translation
(A) ARC is upregulated by BDNF in a Rac1-
dependent manner. Upper panel: immunoblot
analysis of cortical neurons stimulated with
BDNF (100 ng/ml for 30 min) +/– cycloheximide
(CHX, 60 mM for 30 min) or NSC23766 (200 mM
for 10 min pretreatment). Lower panel: ARC pro-
tein levels normalized to GAPDH and expressed
as percentage to vehicle (n = 4, one-way ANOVA
with Holm’s post hoc test, ***p < 0.001). Bars
represent mean ± SEM.
(B) Upregulation of ARC upon BDNF treatment
is protein-synthesis-dependent. Upper panel:
immunoblot analysis of cortical neurons stimulated
with NSC23766 (200 mM for 20 min) or BDNF +/
pretreatment with actinomycin D (Act D) (1 mg/ml
for 30 min) or NSC23766 (200 mM for 10 min) as
indicated above the lanes. Lower panel: quantifi-
cation of ARC protein levels normalized to GAPDH
and expressed as percentage of vehicle control
(n = 3, one-way ANOVA with Holm’s post hoc test,
*p < 0.05, **p < 0.01). Bars represent mean ± SEM.
(C) Synthesis of ARC is altered in Cyfip1 knock-
down, Fmr1 KO, and Fmr1 KO/Cyfip1 knockdown
neurons. Upper panel: immunoblot of cortical
neurons stimulated with BDNF (100 ng/ml for
30 min) +/– NSC23766 (200 mM for 10 min pre-
treatment). Lanes 1–3, scrambled shRNA; lanes
4–6, Cyfip1 shRNA, lanes 7–9, scrambled shRNA
in WT neurons; lanes 10–12, scrambled shRNA in
Fmr1 KO neurons; lanes 13–15, Cyfip1 shRNA in
Fmr1 KO neurons. Lower right panels: basal
expression of CYFIP1, FMRP, and ARC levels
in vehicle-treated neurons. Protein levels were
normalized to GAPDH and shown as percentage
of scrambled shRNA. Grey, Cyfip1 shRNA; gray
stripes, scrambled shRNA in Fmr1 KO; white,
Cyfip1 shRNA in Fmr1 KO (n = 6, one-way ANOVA
with Holm’s post hoc correction, *p < 0.05, ***p <
0.001). Lower right panel: activity-induced
ARC expression. ARC levels after BDNF +/
NSC23766 expressed as percentage to vehicle-
treated neurons. Black, scrambled shRNA; gray,
Cyfip1 shRNA; gray stripes, scrambled shRNA in
Fmr1 KO; white, Cyfip1 shRNA in Fmr1 KO (n = 6,
two-way ANOVA with Holm’s post hoc correction,
*p < 0.05). Bars represent mean ± SEM.
(D) Left panels: ARC level is unaffected in total cortical extracts from Cyfip1+/ mice. Immunoblot of CYFIP1, ARC, and GAPDH in WT (lane 1) and Cyfip1+/
(lane 2) mice. Protein levels were normalized to GAPDH and shown as percentage of WT; white, WT (n = 5); black, Cyfip1+/ n = 3, (Student’s t test, ***p < 0.001).
Right panels: as in the left panels but in synaptoneurosomes (n = 3, Student’s t test, *p < 0.05; **p < 0.01). Bars represent mean ± SEM.
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CYFIP1 in Spine Remodeling and Diseaseused heterozygous animals where CYFIP1 levels are reduced by
40%(Figure 3D).WeexaminedARCexpression inboth total brain
cortex and cortical synaptoneurosomes and found thatCyfip1+/
mice have elevated ARC levels at synapses (Figure 3D).
These data support the hypothesis that FMRP and CYFIP1
regulate protein synthesis downstream of Rac1 activation. Acti-
vated Rac1 reshapes the CYFIP1-eIF4E complex through a
conformational change, so that when translation inhibition is
lifted, more CYFIP1 becomes available for the WRC.
CYFIP1 Affects Spine Morphology
Our results suggest that CYFIP1 complexes have a specific
function in synaptic protein synthesis and actin polymerization.1174 Neuron 79, 1169–1182, September 18, 2013 ª2013 Elsevier IncAs proof of principle, we aimed at uncoupling the two complexes
and studying their contribution to protein translation and actin
polymerization. For this purpose, we designed specific CYFIP1
mutants impairing the interactions with either eIF4E or NCKAP1.
To reduce the CYFIP1-eIF4E interaction, we used a mutant
replacing Lys743 with a Glu (mutant E), which has been shown
to reduce the interaction with eIF4E (Napoli et al., 2008). To inter-
fere with the CYFIP1-NCKAP1 complex, we studied the large
surface of interaction between the two proteins (Chen et al.,
2010), and found two hydrophobic patches on CYFIP1 that fit
to corresponding sites on NCKAP1 (Figure S5B). The second
patch shows a higher complementarity to NCKAP1, in particular
in a stretch of eight consecutive hydrophobic amino acids.
Figure 4. CYFIP1 Deficiency or Mutations
Affecting Interaction with eIF4E or NCKAP1
Alter Synaptic ARC and F-Actin
(A) Dissection of the CYFIP1 interactions with
NCKAP1 (mutD and mutH) or with eIF4E (mutE).
Left panel: IP for YFP-CYFIP1 WT or mutants in
HEK293T cells silenced for endogenous CYFIP1.
Lane 1, input (1/50) from mock-transfected cells;
lanes 2–5, input CYFIP1 siRNA with RNAi-resistant
CYFIP1 WT, mutH, mutD, or mutE (1/50); lane 6,
YFP-IP with mock-transfected cells; lanes 7–10,
YFP-IP for WT, mutH, mutD, or mutE-CYFIP1.
Asterisks indicate exogenous CYFIP1. Central
panel: quantification of CYFIP1-NCKAP1 and
CYFIP1-WAVE1 as percentage of WT (black) for
mutH (red) and mutD (gray). Right panel: quantifi-
cation of CYFIP1-eIF4E as percentage of WT
(black) formutE (white), seealsoNapoli et al. (2008).
(B) Upper panels: CYFIP1 deficiency or mutations
affecting the interaction with eIF4E or NCKAP1
alter synaptic ARC and F-actin levels. Panels show
representative dendritic sections transfected with
scrambled orCyfip1 shRNA (F-GFP, upper panels)
and stained for ARC (red, lower panels) in vehicle or
BDNF-treated neurons. Spines are highlighted in
yellow. Scale bar represents 1 mm. Histogram
represents the ARC immunosignal normalized to
the spine area for neurons transfected as indicated
on the x axis and treated with vehicle (black) or
BDNF (white) (at least n = 150, two-way ANOVA
with Holm’s post hoc test, ***p < 0.001). Lower
panels: as above for F-actin (at least n = 50,
two-way ANOVA with Holm’s post hoc test, *p <
0.05, **p < 0.01, ***p < 0.001). Bars represent
mean ± SEM.
See also Figure S4.
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site for NCKAP1. We therefore designed two mutants: mutant
D, lacking the C-terminal domain that harbors the hydrophobic
patch (aa 922–1251), andmutant H, in which the eight hydropho-
bic residues were replaced by glycines. WT and mutant pro-
teins tagged with the yellow fluorescent protein (EYFP) were
expressed in HEK293T cells (Figure S5C) and displayed correct
cytoplasmic localization (data not shown). To promote the incor-
poration of the exogenous proteins into functional complexes,
we silenced the endogenous Cyfip1 with siRNAs directed
against its 30UTR (Figures 4A and S5D). Both mutant D and
mutant H lost their affinity for NCKAP1 and consequently for
WAVE1, but not for eIF4E, whereas the interaction with eIF4E
was largely decreased with mutant E (Figure 4A), leaving unaf-
fected the binding to NCKAP1 and WAVE1.
To study the contribution of the two CYFIP1 complexes on
ARC synthesis and actin cytoskeleton at synapses, primary
cortical neurons (DIV9) were transfected with scrambled or
Cyfip1 (sh315) shRNA, in combination with CYFIP1 WT, mutant
H (affecting actin polymerization), or mutant E (affecting mRNANeuron 79, 1169–1182, Septranslation). ARC and F-actin were de-
tected by immunolabeling in neurons at
DIV14 with or without BDNF treatment,
and the immunosignal was quantified inspines outlined by the membrane-targeted farnesylated GFP
(F-GFP) carried by the shRNA construct. We found that CYFIP1
downregulation caused augmented ARC synthesis and reduced
F-actin levels in spines (Figure 4B). Moreover, ARC and F-actin
were enhanced after BDNF treatment, but not inCyfip1-silenced
neurons (Figure 4B). Cotransfection of the construct carrying
CYFIP1 WT rescued all defects, both basal and BDNF-induced.
As predicted, basal and inducible ARC expression was restored
bymutant H, but not bymutant E. F-actin levels, in contrast, were
rescued bymutant E, but not by mutant H. The fact that mutant E
rescued F-actin expression but remains insensitive to BDNF
stimulation (Figure 4B) might suggest that this pathway requires
local translation in addition to WRC activation. In conclusion, the
data demonstrate that the CYFIP1 mutants are valuable in sepa-
rating the two functions of CYFIP1 in the regulation of local pro-
tein translation and the control of actin cytoskeleton at synapses.
Alterations in factors controlling protein synthesis (e.g., FMRP)
or actin remodeling (e.g., WAVE1) cause dendritic spine defects
(Irwin et al., 2001; Kim et al., 2006). Therefore, we addressed the
question of whether CYFIP1 plays a role in dendritic spinetember 18, 2013 ª2013 Elsevier Inc. 1175
Figure 5. CYFIP1 Is Required for Correct
Spine Morphology
(A) Dendritic spines are defective in ex vivo cortical
neurons from Cyfip1+/ mice. Cortical neurons
were labeled with DiI by diolistic staining on brain
slices. Panels show representative dendritic sec-
tions; scale bar represents 5 mm. Insets in the
lower panel represent magnification of individual
spines classified as mature (stubby and mush-
room-like) and immature (long thin and filopodia).
Scale bar represents 0.5 mm.
(B) Dendritic spine morphology in cortical neurons
from WT (black) or Cyfip1+/ (white) animals. Dis-
tribution of spines as percentage is shown (n = 282
WT; n = 310 Cyfip1+/; c2 test, *p < 0.05). Bars
represent mean ± SEM.
(C) Mean spine length in WT and Cyfip1+/ neu-
rons (Student’s t test, ***p < 0.001). Bars represent
mean ± SEM.
(D) Dendritic spines are altered in cultured cortical
neurons silenced for Cyfip1. Outline of dendritic
shafts from DIV14 primary cortical neurons trans-
fected with scrambled, two Cyfip1 shRNAs
(shRNA 319, 315), or shRNA 315 cotransfected
with RNAi-resistant CYFIP1 WT, mutD, mutH, or
mutE. Panels show representative dendritic sec-
tions; scale bar represents 5 mm.
(E) Dendritic spine morphology of neurons shown
in (D), expressed as percentage of mature
(in black, stubby + mushroom-like) and immature
(in white, long thin + filopodia) spines (at least
ten neurons/condition, c2 test, ***p < 0.001).
(F) Upper panel: mean spine length of neurons
shown in (D) (one-way ANOVA with Bonferroni
correction, ***p < 0.001). Lower panel: Cumulative
probability plots for mean spine length. Bars
represent mean ± SEM.
See also Figure S5.
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isolated from Cyfip1+/– and WT littermates, and individual neu-
rons were labeled diolistically. Dendritic spines were measured
and assigned to four morphological classes, namely mature
(stubby and mushroom) and immature types (long thin and filo-
podia). Neurons displayed a spine distribution in agreement
with previous ex vivo studies (Galvez andGreenough, 2005; Irwin
et al., 2002). Neurons from Cyfip1+/– mice, despite the mild
reduction in CYFIP1, showed an increased population of filopo-
dia (Figures 5A–5C), but no defects in spine density and head
width (data not shown). To reduce CYFIP1 expression more
drastically, primary cortical neurons (DIV9) were silenced1176 Neuron 79, 1169–1182, September 18, 2013 ª2013 Elsevier Inc.for Cyfip1 (sh319 and sh315, or scram-
bled shRNA), and spine density and
morphology were examined at DIV14.
Neuronal morphology was outlined by a
farnesylated GFP (F-GFP) carried by the
shRNA construct (Figures 5A–5D and
S5E). Spines were classified as above.
Spine number and spine measurements
in cortical neurons treated with scram-
bled shRNA were consistent with previ-ous reports (Papa et al., 1995). Spine density did not differ
significantly between scrambled and Cyfip1 shRNA neurons
(not shown). However, Cyfip1 knockdown robustly affected
spine morphology: spines with mature phenotype (i.e., ‘‘stubby’’
and ‘‘mushroom’’) were significantly reduced in Cyfip1-silenced
neurons compared to control, whereas elongated, immature-
looking spines increased in number (Figures 5D, 5E, S5E, and
S5F). Mean head width was unchanged (not shown), but mean
spine length was increased as a consequence of Cyfip1
silencing; cumulative probability plots corroborated these re-
sults (Figure 5F). To exclude the possibility that the phenotype
might be due to off-target effects, we performed a rescue
Figure 6. The CYFIP1 Interactome in Mouse
Cortex and Synapses and Its Relevance for
Neuropsychiatric Disorders
(A) CYFIP1 interactome, as revealed by MS of
the proteins coimmunoprecipitating with CYFIP1
in cortical whole-cell lysate. IP with rabbit IgGs
was used as a negative control; n = 3. The identi-
fied proteins are listed in Table S2, Table S3.
(B) Validation of CYFIP1 interactors by reverse IP.
Lane 1, input (1/100); lanes 2–6, specific IPs; lanes
7–8, controls with rabbit andmouse IgGs. See also
Figure S6.
(C) CYFIP1 interactome is partially RNase sensi-
tive. Lane 1, input (1/50); lane 2, CYFIP1 IP; lane 3,
CYFIP1 IP after RNase treatment; lane 4, control IP
(rabbit IgGs); n = 5.
(D) Outcome of MS analysis of the proteins coim-
munoprecipitating with CYFIP1 in cortical syn-
aptoneurosomes. IPs with rabbit IgGs were used
as negative control; n = 6. The identified proteins
are listed in Table S4.
(E) Many CYFIP1 interactors are linked to neuro-
logical diseases. Indicated are the percentages of
genes related to intellectual disability (ID), autism
spectrum disorder (ASD), attention deficit hyper-
activity disorder (ADHD), schizophrenia (SCZ),
major depressive disorder (MDD), and Alzheimer’s
disease (AD) (the diagram is approximate, as some
genes are related to more than one disease; see
also Table S5).
(F) Proposed model for the interplay of CYFIP1
complexes in brain. In neurons, CYFIP1 is asso-
ciated with two distinct protein complexes, the
CYFIP1-FMRP-eIF4E, which represses transla-
tion of specific mRNAs such as Arc/Arg3.1mRNA,
and the WRC (CYFIP1-NCKAP1-WAVE1-ABI2-
HSPC300), which regulates actin remodeling. BDNF signaling activates Rac1, and GTP-Rac1 changes the equilibrium between the two CYFIP1 complexes
by inducing a conformational change that releases CYFIP1 from eIF4E and relocates it to active WRC. As a consequence, actin cytoskeleton is remodeled and,
concomitantly, the translation of proteins that encode cytoskeleton elements and synaptic function and plasticity is activated. The two processes converge to
regulate proper spine morphology, which is compromised by perturbations of CYFIP1 expression or interference with CYFIP1-eIF4E and CYFIP1-WRC.
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CYFIP1 in Spine Remodeling and Diseaseexperiment by cotransfecting the sh315 (against Cyfip1 30UTR)
and the Cyfip1 WT coding sequence. The construct was able
to restore normal CYFIP1 levels (Figure S5E), and consequently
proper spine distribution (Figures 5D, 5E, and S5F) and mean
spine length (Figure 5F).
Finally, we aimed at investigating the contribution of CYFIP1-
eIF4E and WRC to spine formation. Therefore, we cotransfected
the CYFIP1 mutants validated above with Cyfip1 sh315 to
knockdown the endogenous protein (Figure S5E), and analyzed
dendritic spine morphology. All mutants failed to restore the
normal spine distribution and spine length (Figures 5D, 5F, and
S5F), indicating that both CYFIP1 complexes are equally impor-
tant for proper spine formation.
In conclusion, CYFIP1 deficiency alters the proper func-
tioning of two complexes modulating critical synaptic pro-
cesses, i.e., protein synthesis and actin cytoskeleton remodel-
ing, both of these ultimately leading to defects in spine
morphology.
CYFIP1 Interactome Is Linked to Human Disease
To further expand the knowledge of CYFIP1 in the brain, we
studied its interactome in mouse cerebral cortex through immu-Neunoprecipitation with a specific anti-CYFIP1 antibody and tandem
mass spectrometry (MS). In whole cortical lysates, we identified
a total of 27 CYFIP1-associated proteins, of which 74% are
RNA-binding proteins (RBPs) (Figure 6A), comprising either
known (FMRP and PABP-1) (Napoli et al., 2008; Schenck et al.,
2003) or novel (ELAV-like proteins, Caprin1 and hnRNPQ/
SYNCRIP) partners; these are listed in Tables S2 and S3.
The association of some interactors (ELAVL4, PABP1, Caprin1,
SYNCRIP, FMRP, eIF4E, and DCTN1) was validated by reverse
immunoprecipitation (Figures 6B and S6). To investigate whether
these interactions depend upon RNA, CYFIP1 was immuno-
precipitated from RNase-treated cortical lysates. Whereas
the binding of CYFIP1 to PABP1, DCTN1 and eIF4E was
not compromised by RNA degradation, the interaction with
SYNCRIP, ELAVL4, and ELAVL1 was no longer detected (Fig-
ure 6C) implying that the CYFIP1 complexes contain both protein
and RNA molecules. The association of FMRP with CYFIP1 was
slightly reduced by treatment with RNase, confirming previous
indications that RNAs (e.g., BC1) can strengthen this interaction
(Napoli et al., 2008) In conclusion, the mouse cortical CYFIP1
interactome consists mainly of proteins that regulate mRNA
metabolism and translation.ron 79, 1169–1182, September 18, 2013 ª2013 Elsevier Inc. 1177
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immunoprecipitated CYFIP1 frommouse cortical synaptoneuro-
somes. Sixteen proteins were identified by MS, seven of which
had not been detected in the cortical lysate data set likely
because they are enriched in the CYFIP1 complexes in the syn-
aptic compartment. The synaptic CYFIP1 interactome contained
not only RBPs, but also cytoskeleton-related proteins, including
components of the WRC (NCKAP1, ABI1/2, and WAVE1; Fig-
ure 6D; Tables S3 and S4). These results further demonstrate
that CYFIP1 is active in regulating mRNA translation and deter-
mining cytoskeleton-based cell morphology.
Deletions and duplications of a chromosomal region including
CYFIP1 have been linked to ID, ASD, and schizophrenia
(Cooper et al., 2011; Doornbos et al., 2009; Leblond et al.,
2012; Murthy et al., 2007; Nowicki et al., 2007; Tam et al.,
2010; van der Zwaag et al., 2010; von der Lippe et al., 2010;
Zhao et al., 2012). We reasoned that proteins in the same
protein network might have a similar pathological effect. A
literature search on disease involvement of the genes in
question revealed that 25 out of the 40 proteins that bind
CYFIP1 are encoded by genes associated with ID, ASD,
ADHD, schizophrenia, major depressive disorder, and Alz-
heimer’s disease (Tables S4 and S5). In addition, a gene-based
analysis interrogating for association with schizophrenia based
on the meta-analytic p values obtained by the largest schizo-
phrenia genome-wide association study to date (Ripke et al.,
2011) (9,394 cases and 12,462 controls) revealed that 8 out of
36 tested autosomal genes of the CYFIP1 interactome had a
nominally significant p value (<0.05) for association with schizo-
phrenia (Tables S4–S6). This significantly exceeds the expec-
tation (1.8 genes) under the null hypothesis of no association
(one-sided Fisher’s exact test, p = 0.042), although the poly-
genic nature of schizophrenia should be considered. One
gene, FAM120A, was significantly associated with schizo-
phrenia (p = 0.00064) after Bonferroni correction for testing
36 genes. In summary, 25 proteins out of 40 identified in
our CYFIP1 interactome are encoded by genes involved in
diseases: 26% are associated with schizophrenia, 19% with
ASD, and 10% with ID (Table S4; Figure 6E). These observa-
tions suggest that CYFIP1 and its interaction partners are linked
to pathways that, if impaired, can be associated with intellectual
disabilities and psychiatric disorders.
DISCUSSION
CYFIP1 is present in two functional complexes essential for syn-
aptic morphology and function: a ribonucleoparticle repressing
protein synthesis and the WAVE regulatory complex (Figure 6F).
When CYFIP1 interacts with NCKAP1 forming a platform for the
assembly of the WRC, the interaction with eIF4E is obstructed
and vice versa. The segregation into the two complexes relies
on alternative CYFIP1 conformations, a planar one needed for
the WRC (Chen et al., 2010), and a more globular one for the
interaction with eIF4E. BDNF, a neurotrophin and synaptic plas-
ticity-inducing factor, able to induce protein synthesis (Takei
et al., 2004) and cytoskeleton rearrangements (Bramham,
2008), reduces the pool of CYFIP1 repressing translation and
concomitantly increases the amount of CYFIP1 recruited on1178 Neuron 79, 1169–1182, September 18, 2013 ª2013 Elsevier Incthe WRC. This event is regulated by Rac1 and is facilitated by
a conformational change, as shown by FRET experiments: after
BDNF administration, CYFIP1 switches from a more globular
form to a planar conformation suitable for incorporation in the
WRC. As a consequence, CYFIP1 is freed from eIF4E and the
synthesis of key modulators of synaptic plasticity such as ARC
is activated (Figure 6F). Enhanced expression of ARC, in the
absence of CYFIP1 or FMRP, might alter AMPA receptor endo-
cytosis and affect the actin cytoskeleton, therefore affecting
synaptic structure and physiology (Shepherd and Bear, 2011).
Concomitant to ARC induction, active Rac1 promotes CYFIP1
recruitment to the WRC and thus actin polymerization. In line
with our evidence, Rac1 activation was shown to translocate
CYFIP1 to actin-rich domains involved in cellular protrusions in
mouse fibroblasts (Castets et al., 2005). Also, CYFIP1 overex-
pression in Drosophila rescues eye defects caused by a consti-
tutively active Rac1 mutant (Schenck et al., 2003); in light of
our results, this overexpression might improve the balance in
CYFIP1 partitioning between the two complexes caused by the
increased Rac1 signaling.
Dendritic spine maturation is critical for correct brain func-
tioning (Penzes et al., 2011). We show here that CYFIP1 deple-
tion severely affects dendritic spine morphology both in vivo
and in vitro, causing an unbalanced ratio between mature and
immature spines (Figures 4 and 5). Downregulation of Cyfip1
causes defects in ARC synthesis and actin polymerization in
dendritic spines (Figures 3 and 4). Altering CYFIP1 incorporation
in the WRC (as with mutant H) affects F-actin polymerization but
not ARC synthesis; conversely, when the CYFIP1-eIF4E inter-
action is impaired (as with mutant E), ARC synthesis is altered
with no effect on F-actin levels (Figure 4). Our studies reveal
that correct spine morphology requires both intact CYFIP1-
eIF4E and CYFIP1-WRC complexes, and that correct coordina-
tion between the two is essential for proper ARC synthesis, actin
polymerization, and finally spine morphology (Figures 5 and 6).
Effects of CYFIP1 reduction on dendritic spines are compatible
with the enhancedmGluR-dependent LTD and behavioral abnor-
malitiescausedbyCyfip1haploinsufficiency (Bozdagi etal., 2012),
similar to the phenotype observed in Fmr1 KO mice (Bear et al.,
2004). ARC is required formGluR-LTD and AMPAR internalization
(Waungetal., 2008), andweshowthatCyfip1+/micehaveexces-
sive ARC at synapses (Figure 3D). Furthermore, the observed
spine dysmorphogenesis is in line with defects in the WRC
components (Grove et al., 2004; Kim et al., 2006; Soderling
et al., 2007), loss of FMRP (Comery et al., 1997; Cruz-Martı´n
et al., 2010; Galvez andGreenough, 2005; Irwin et al., 2002), over-
expression of ARC (Peebles et al., 2010), or Rac1 blockade during
early development (Tashiro and Yuste, 2004). All these pheno-
types overlap, without being identical, indicating that CYFIP1 is
at the hub of more than one spine-controlling pathway.
Spine dysmorphogenesis is a common feature of several
neuropsychiatric disorders (Penzes et al., 2011). Of note,
FMRP- and CYFIP1-linked disorders are characterized by spine
dysmorphogenesis that we show here is caused by an imbal-
ance of protein synthesis and actin remodeling. CYFIP1 is impli-
cated in ID (Cooper et al., 2011; Napoli et al., 2008; Nowicki et al.,
2007; Schenck et al., 2003), ASD (Cooper et al., 2011; Doornbos
et al., 2009; Murthy et al., 2007; Nishimura et al., 2007; Sahoo.
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CYFIP1 in Spine Remodeling and Diseaseet al., 2006; van der Zwaag et al., 2010; von der Lippe et al.,
2010), and SCZ (Tam et al., 2010; Zhao et al., 2012). Consistently
with the idea that related human disorders might share genetic
causes because they are due to perturbations of highly intercon-
nected cellular networks (Vidal et al., 2011), we find that
the CYFIP1 interactome is enriched in genes implicated in ID,
ASD, SCZ, ADHD, MDD, and AD. Importantly, the two key
CYFIP1 interactors examined here, NCKAP1 and eIF4E, have
been shown to be genetically associated with ASD (Iossifov
et al., 2012; Neves-Pereira et al., 2009). Our findings suggest
that mutations in the CYFIP1 network might explain part of the
autistic features observed in FXS patients (Farzin et al., 2006),
which can also suffer from psychosis (Reiss et al., 1986).
Mutations in the genes of the CYFIP1 interactome might per-
turb the homeostasis of the interaction networks, regulating
translation versus cytoskeleton remodeling, thereby triggering
a spectrum of pathological processes at synapses that can
lead to a broad range of clinical manifestations, such as
intellectual disabilities, autism, and schizophrenia.
EXPERIMENTAL PROCEDURES
Animal Care, Strain, and Stage
Animal care was conducted according to the Belgian law of August 14th, 1986,
concerning the protection and well-being of animals, and the following Konin-
klijk Besluit (K.B.) of November 14th, 1993 and K.B of September 13th, 2004,
as well as to the European Community Council Directive 86/609, Oja L 358, 1,
December 12, 1987, and international guidelines (European Community Coun-
cil Directive 86/609, Oja L 358, 1, December 12, 1987; National Institutes of
Health Guide for the Care and Use of Laboratory Animals, US National
Research Council, 1996). One-month-old C57BL/6J Fmr1 KO and WT control
littermates were used for the EM-IHC control.
WT mice used in this study were 3- to 4-week-old males C57BL/6J. Two-
month-old Cyfip1+/ 129/Sv C57BL/6J and WT control littermates were used
for diolistic staining on brain slices.
Immunoprecipitation
Immunoprecipitation (IP) was performed as previously described (Napoli et al.,
2008). For details see the Supplemental Experimental Procedures.
Neuronal Transfection
Mouse primary cortical neurons (DIV9) were transfectedwith plasmids carrying
scrambled or Cyfip1 shRNA and Cyfip1WT or mutants using a calcium phos-
phate method (Sans et al., 2003). At DIV14, neurons were fixed for 20 min in
PFA/SEM (4% PFA, 0.12 M sucrose, 3 mM EGTA, 2 mM MgCl2 in PBS).
Immunofluorescence
Primary cortical neurons were fixed with 4% paraformaldehyde (PFA/SEM),
permeabilized with 0.2% Triton X-100, and incubated overnight with the anti-
bodies, as indicated in the Supplemental Experimental Procedures. Confocal
images were obtained as described in the Supplemental Experimental
Procedures.
Immunoblotting
Immunoblotting was performed using standard protocols. Antibodies list and
usage is described in the Supplemental Experimental Procedures.
Diolistic Staining of Ex Vivo Brain Slices
See the Supplemental Experimental Procedures.
Imaging
A confocal laser-scanning microscope (Nikon) with 403 or 603 oil objectives
with sequential acquisition setting at 2,0483 2,048 pixels resolution was used.NeuFor immunofluorescence (IF), only a z series was acquired; for spine analysis,
each image was a z series projection, of 7 to 9 images each, averaged two
times and taken at 0.8 mm depth intervals.
Dendritic Spines Analysis
Images were processed and analyzed with ImageJ 1.44 software. Five 20 mm
segments starting at least 25 mm from the cell soma were analyzed for each
neuron. F-EGFP or DiI staining was used to outline the profile of the dendritic
shaft and protrusions. Maximal spine head width (WH), neck width (WN), and
length (L) were measured for each dendritic protrusion. Spines were defined
as follows: Stubby (L % 1 mm), Mushroom (1 < L % 3 mm; WH R 2 3 WN),
Long Thin (1 < L% 3 mm; WH < 23WN), and Filopodia (3 < L% 5 mm). At least
ten randomly chosen neurons/condition from three independent cultures were
imaged for quantification. Counts and data analysis were conducted blind to
experimental condition.
Synaptoneurosomes Purification and Stimulation
Cortical synaptoneurosomes were prepared as previously described (Napoli
et al., 2008). Pre- and postsynaptic fractions were isolated from cortical
synaptoneurosomes as previously described (Phillips et al., 2001). See the
Supplemental Experimental Procedures for details.
Neuronal Cell Cultures and BDNF Stimulation
Primary mouse cortical neurons were prepared as previously described (Fer-
rari et al., 2007). See the Supplemental Experimental Procedures for details
and treatments with BDNF, cycloheximide, and actinomycin D (Sigma).
m7GTP Chromatography
The procedure was slightly modified from Napoli et al. (2008). See the Supple-
mental Experimental Procedures for details.
DNA Constructs
See the Supplemental Experimental Procedures.
Lentiviral Production to Silence Cyfip1
HEK293T cells were used as packaging cells and transfected by the calcium
phosphate method (Chen and Okayama, 1987) with second generation plas-
mids (pLKO.1, Mission shRNA, Sigma-Aldrich) (Naldini et al., 1996) carrying
scrambled orCyfip1 shRNAs. See the Supplemental Experimental Procedures
for details.
FRET/FLIM Experiment in Primary Neurons
Mouse primary cortical neurons (DIV 9) were transfected with the indicated
DNA constructs using Lipofectamine 2000. Neurons were treated with
100 nM of the panTrk inhibitor K252a for 24 hr or 100 ng/ml BDNF for
30 min. Coverslips were then fixed with 4% PFA for 20 min, washed with
PBS, incubated with 1 M NH4Cl for 15 min, washed, and then mounted with
Mowiol. A construct carrying a tandem mCherry-EGFP was used as positive
control for intramolecular FRET. Two constructs carrying mCherry and EGFP
(Clontech) separately were cotransfected to provide a negative control.
FRET/FLIM measurements were performed as in Zhang et al. (2013). For
details see the Supplemental Experimental Procedures.
Computational Studies
See the Supplemental Experimental Procedures.
Disease Annotation and Gene-Based Analyses
See the Supplemental Experimental Procedures.
Statistics
Comparisons between two groups were performed using one-sample or two-
sample two-tailed Student’s t test. One-way or two-way ANOVA followed by
post hoc Student’s t test with Holm’s or Bonferroni correction were used for
multiple comparisons. Distributions were analyzed using Pearson’s c2 test.
Comparisons between cumulative probability plots were performed using
two-sample Kolgomorov-Smirnov (K-S) test. Significance was accepted to
p < 0.05. Bars represent SEM.ron 79, 1169–1182, September 18, 2013 ª2013 Elsevier Inc. 1179
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Supplemental Information includes Supplemental Experimental Procedures,
six figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2013.06.039.
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